A Phase 2 Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers
Phase of Trial: Phase II
Latest Information Update: 07 Mar 2018
At a glance
- Drugs Trastuzumab emtansine (Primary)
- Indications Bladder cancer; Lung cancer; Solid tumours
- Focus Therapeutic Use
- Acronyms Basket
- 02 Mar 2018 Planned End Date changed from 1 Feb 2018 to 1 Feb 2019.
- 02 Mar 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
- 18 Oct 2017 Results of a cohort of patients with advanced HER2 mutant or amplified lung cancers (n=33) presented at the 18th World Conference on Lung Cancer